|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Goldstraw P, Ball D, Jett JR, Le Chevalier
T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer.
Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Naim Younes R, Gross JL, Abrao FG and
Rodrigues Pereira J: Impact of adjuvant chemotherapy in completely
resected stage IIIA non-small cell lung cancer. Minerva Chir.
68:169–174. 2013.
|
|
4
|
Filipits M and Pirker R: Predictive
markers in the adjuvant therapy of non-small cell lung cancer. Lung
Cancer. 74:355–363. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jemal A, Murray T, Ward E, et al: Cancer
statistics, 2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar
|
|
6
|
Pisters KM: Adjuvant chemotherapy for
non-small-cell lung cancer - the smoke clears. N Engl J Med.
352:2640–2642. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ost D, Goldberg J, Rolnitzky L and Rom WN:
Survival after surgery in stage IA and IB non-small cell lung
cancer. Am J Respir Crit Care Med. 177:516–523. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhong GC, Yan B, Sun Y, et al: Clinical
efficacy of immunotherapy of dendritic cell and cytokine-induced
killer cell combined with chemotherapy for treatment of multiple
myeloma. Zhonghua Xue Ye Xue Za Zhi. 33:1000–1003. 2012.(In
Chinese).
|
|
9
|
Zhan HL, Gao X, Pu XY, Li W, Li ZJ, Zhou
XF and Qiu JG: A randomized controlled trial of postoperative tumor
lysate-pulsed dendritic cells and cytokine-induced killer cells
immunotherapy in patients with localized and locally advanced renal
cell carcinoma. Chin Med J (Engl). 125:3771–3777. 2012.
|
|
10
|
Shi SB, Ma TH, Li CH and Tang XY: Effect
of maintenance therapy with dendritic cells: cytokine-induced
killer cells in patients with advanced non-small cell lung cancer.
Tumori. 98:314–319. 2012.PubMed/NCBI
|
|
11
|
Sargent D, Shi Q, Yothers G, et al;
Adjuvant Colon Cancer End-points (ACCENT) Group. Two or three year
disease-free survival (DFS) as a primary end-point in stage III
adjuvant colon cancer trials with fluoropyrimidines with or without
oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC,
X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer. 47:990–996.
2011.
|
|
12
|
Fidler MJ, Kim AW, Zusag T and Bonomi P:
Treatment of locally advanced non-small cell lung cancer. Clin Adv
Hematol Oncol. 7:455–464. 479–480. 2009.
|
|
13
|
Juretic A, Sobat H and Samija M: Combined
modality therapy of non-small cell lung cancers. Ann Oncol.
10(Suppl 6): 93–98. 1999. View Article : Google Scholar
|
|
14
|
Seder CW, Allen MS, Cassivi SD, et al:
Stage IIIA non-small cell lung cancer: morbidity and mortality of
three distinct multimodality regimens. Ann Thorac Surg.
95:1708–1716. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carney DN: Lung cancer - time to move on
from chemotherapy. N Engl J Med. 346:126–128. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yuan XK, Zhao XK, Xia YC, Zhu X and Xiao
P: Increased circulating immunosuppressive
CD14+HLA-DR−/low cells correlate with
clinical cancer stage and pathological grade in patients with
bladder carcinoma. J Int Med Res. 39:1381–1391. 2011.PubMed/NCBI
|
|
17
|
Ren J, Di L, Song G, et al: Selections of
appropriate regimen of high-dose chemotherapy combined with
adoptive cellular therapy with dendritic and cytokine-induced
killer cells improved progression-free and overall survival in
patients with metastatic breast cancer: reargument of such
contentious therapeutic preferences. Clin Transl Oncol. 15:780–788.
2013.
|
|
18
|
Shi L, Zhou Q, Wu J, Ji M, Li G, Jiang J
and Wu C: Efficacy of adjuvant immunotherapy with cytokine-induced
killer cells in patients with locally advanced gastric cancer.
Cancer Immunol Immunother. 61:2251–2259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sangiolo D, Mesiano G, Carnevale-Schianca
F, Piacibello W, Aglietta M and Cignetti A: Cytokine induced killer
cells as adoptive immunotherapy strategy to augment graft versus
tumor after hematopoietic cell transplantation. Expert Opin Biol
Ther. 9:831–840. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng YW, Li RM, Zhang XW and Ren XB:
Current adoptive immunotherapy in non-small cell lung cancer and
potential influence of therapy outcome. Cancer Invest. 31:197–205.
2013. View Article : Google Scholar : PubMed/NCBI
|
